Oxford Biomedica will make extra production suites at its Oxbox facility available to AstraZeneca to service an expanded coronavirus vaccine manufacturing agreement. AstraZeneca originally hired UK-based contract development and manufacturing organization (CDMO) Oxford Biomedica for the commercial production of the vector-based COVID-19 vaccine candidate, AZD1222 in May. Last week, the Anglo-Swedish biopharmaceutical firm paid an additional £15 million ($20 million) upfront to reserve up to three more manufacturing suites for 18 months. The deal can be extended by mutual agreement.…